These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 25197000)
1. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer. Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000 [TBL] [Abstract][Full Text] [Related]
2. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Bandiera E; Zanotti L; Fabricio AS; Bucca E; Squarcina E; Romani C; Tassi R; Bignotti E; Todeschini P; Tognon G; Romagnolo C; Gion M; Sartori E; Maggino T; Pecorelli S; Ravaggi A Clin Chem Lab Med; 2013 Sep; 51(9):1815-24. PubMed ID: 24013103 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
4. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors. Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814 [TBL] [Abstract][Full Text] [Related]
5. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses. Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232 [TBL] [Abstract][Full Text] [Related]
6. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Kristjansdottir B; Levan K; Partheen K; Sundfeldt K Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789 [TBL] [Abstract][Full Text] [Related]
8. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033 [TBL] [Abstract][Full Text] [Related]
9. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease. Zheng H; Gao Y Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406 [TBL] [Abstract][Full Text] [Related]
10. Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer. Wu X; Li D; Liu L; Liu B; Liang H; Yang B Arch Gynecol Obstet; 2014 Jun; 289(6):1309-14. PubMed ID: 24370956 [TBL] [Abstract][Full Text] [Related]
12. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831 [TBL] [Abstract][Full Text] [Related]
13. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer. Wang B; Yu L; Yang GZ; Luo X; Huang L Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer. Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638 [TBL] [Abstract][Full Text] [Related]
15. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses? Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000 [TBL] [Abstract][Full Text] [Related]
16. Evaluating the clinical significances of serum HE4 with CA125 in peritoneal tuberculosis and epithelial ovarian cancer. Zhang L; Chen Y; Liu W; Wang K Biomarkers; 2016; 21(2):168-72. PubMed ID: 26667154 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum mesothelin in malignant and benign ovarian masses. Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964 [TBL] [Abstract][Full Text] [Related]
18. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715 [TBL] [Abstract][Full Text] [Related]